Rami Komrokji, MD
H. Lee Moffitt Cancer Center and Research Institute
5
4
3
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Martha Wadleigh, MD
Dana-Farber Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
Bik To, MD
Royal Adelaide Hospital
Shared therapeutic areas:
Worked with same sponsors:
John Seymour, M.D.
Peter MacCallum Cancer Centre, Australia
Shared therapeutic areas:
Worked with same sponsors:
Andrew Roberts, M.D.
Melbourne Health
Shared therapeutic areas:
Worked with same sponsors:
Ruben Mesa, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Azra Raza, MD
Columbia University
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
All 5 trials loaded